New MRD Assessment Data Using clonoSEQ® To Be Presented at 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Read More

Pharma Services

Research & Development

Adaptive’s T-cell receptor (TCR) and B-cell receptor (BCR) sequencing assay provides a quantitative end-to-end immunosequencing solution that helps pharma partners discover the breadth and depth of the adaptive immune repertoire.

Key Applications of These
Immune Receptor Data

Clone Tracking

Track T or B cell receptors from diverse samples, pre- and post-treatment and over time.

Repertoire Properties

Identify highly expanded clones and diversity of the repertoire.

Public Clones

Determine shared receptor amino acid sequences.

Immune Repertoire Overlap

Detect clonal overlap between different samples or across different time points.

T-cell Fraction

View and monitor changes in T-cell fraction over time or between samples.


Map enhanced sequences to

Use in the Drug Discovery
and Development Process

We work with our partners across the research and development value chain. The rich immune receptor data that we generate provides valuable insights to inform and accelerate preclinical and clinical drug development— potentially saving significant cost and time. 

CAR-T Development
and Monitoring

In March 2022, the US. Food & Drug Administration (FDA) issued draft guidance for institutions developing CAR T cell therapies. This guidance includes specific recommendations to various phases and stages of CAR T cell development—including in preclinical testing, CMC/manufacturing and monitoring of these “living medicines” for up to 15 years following infusion in patients.

Patient’s Repertoire

  • Clonality analysis of a patient’s repertoire prior to treatment with either TCR and CAR-T therapy
  • Infer and confirm subject HLA prior to therapy

Infusion Product

  • Clonality assessment of the product to prevent potential severe adverse events 
  • Monitor infusion product throughout the manufacturing process


  • Monitor expansion and persistence of product in blood vs. site of disease
  • Determine biomarkers of response (e.g., magnitude and durability)